Skip to main content

Table 3 sRAGE in 200 COPD patients (univariate analysis)

From: Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study

Characteristics n Median IQR P-value
Smoking habits     
Current smoker 97 677 483-1076 0.777
Former smoker 103 638 492-1063  
Pack-years of smoking     
>48 96 628 449-1055 0.479
≤48 104 669 484-1076  
FEV 1 , % predicted     
≥50 122 660 503-1078 0.015
<50 62 763 538-1138  
<30 16 435 247-544  
DL CO , % predicted     
>76 96 745 546-1051 0.007
≤76 104 612 428-1076  
Emphysema     
No or mild 119 715 532-1174 0.003
Moderate 56 644 482-1041  
Severe 25 465 243-644  
Chronic cor pulmonale     
yes 47 534 321-741 0.002
no 153 715 529-1164  
Systemic arterial hypertension     
yes 95 658 484-1064 0.999
no 105 644 477-1076  
Coronary artery disease     
yes 59 681 560-1040 0.352
no 141 631 465-1087  
Heart failure     
yes 23 886 583-1252 0.376
no 177 641 465-1039  
Diabetes mellitus     
yes 22 920 735-1123 0.003
no 178 630 475-1069  
Dyslipidemia     
yes 61 681 508-1078 0.539
no 139 631 480-1062  
Inhaled corticosteroids     
yes 128 642 482-1076 0.880
no 72 671 484-1078  
Statins     
yes 37 681 558-1033 0.713
no 163 641 470-1082  
  1. Definitions of abbreviations: sRAGE = soluble receptor for advanced glycation end products (pg/mL); IQr = interquartile range. For the other abbreviations see table 1. The cutpoints of FEV1 % predicted are based on GOLD stage (see ref. [1]). The cutpoints for pack-years of smoking and DLCO % predicted are the median value in the whole sample.